These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25380674)

  • 1. Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.
    O'Leary O; Nolan Y
    CNS Drugs; 2015 Jan; 29(1):1-15. PubMed ID: 25380674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen synthase kinase-3 as a key regulator of cognitive function.
    Fan X; Zhao Z; Wang D; Xiao J
    Acta Biochim Biophys Sin (Shanghai); 2020 Mar; 52(3):219-230. PubMed ID: 32147679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glycogen synthase kinase-3β enhances cognitive recovery after stroke: the role of TAK1.
    Venna VR; Benashski SE; Chauhan A; McCullough LD
    Learn Mem; 2015 Jul; 22(7):336-43. PubMed ID: 26077686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.
    Thotala DK; Hallahan DE; Yazlovitskaya EM
    Cancer Res; 2008 Jul; 68(14):5859-68. PubMed ID: 18632640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
    Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
    Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.
    King MK; Pardo M; Cheng Y; Downey K; Jope RS; Beurel E
    Pharmacol Ther; 2014 Jan; 141(1):1-12. PubMed ID: 23916593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of glycogen synthase kinase-3beta in schizophrenia.
    Koros E; Dorner-Ciossek C
    Drug News Perspect; 2007 Sep; 20(7):437-45. PubMed ID: 17992266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase 3: an emerging therapeutic target.
    Eldar-Finkelman H
    Trends Mol Med; 2002 Mar; 8(3):126-32. PubMed ID: 11879773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.
    Medina M; Avila J
    Expert Opin Ther Targets; 2014 Jan; 18(1):69-77. PubMed ID: 24099155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Glycogen Synthase Kinase-3: An Emerging Target in the Treatment of Traumatic Brain Injury.
    Shim SS; Stutzmann GE
    J Neurotrauma; 2016 Dec; 33(23):2065-2076. PubMed ID: 26979735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
    Palomo V; Martinez A
    Expert Opin Ther Pat; 2017 Jun; 27(6):657-666. PubMed ID: 27828716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.
    Medina M; Avila J
    Expert Rev Neurother; 2013 May; 13(5):495-503. PubMed ID: 23621307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
    Manduca JD; Thériault RK; Perreault ML
    Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.
    Martinez A; Castro A; Dorronsoro I; Alonso M
    Med Res Rev; 2002 Jul; 22(4):373-84. PubMed ID: 12111750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activator or inhibitor? GSK-3 as a new drug target.
    Takahashi-Yanaga F
    Biochem Pharmacol; 2013 Jul; 86(2):191-9. PubMed ID: 23643839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.